Research and Markets: Genentech's Rituxan Has Generated Strong Growth in the NHL Market since Its Launch, Although Rituxan's Market Penetration May Have Peaked - New Approaches To The Treatment Of Non-Hodgkin's Lymphoma.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47405) has announced the addition of New Approaches to the Treatment of Non-Hodgkin's Lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma to their offering. Non-Hodgkin's lymphoma, consisting of 29 different malignancies of the lymphatic system lymphatic system (lĭmfăt`ĭk), network of vessels carrying lymph, or tissue-cleansing fluid, from the tissues into the veins of the circulatory system. , is a devastating dev·as·tate tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates 1. To lay waste; destroy. 2. To overwhelm; confound; stun: was devastated by the rude remark. disease: although treatable, only a small percentage of these cancers are curable cur·a·ble adj. Capable of being cured or healed. , and median survival of aggressive NHLs is poor. While treatment has greatly improved since the introduction of Genentech's Rituxan in 1997, considerable unmet treatment needs remain, spurring significant development in NHL NHL Non-Hodgkin's lymphoma, see there therapies. Get the Answers You Need to Shape Your Strategy Genentech's Rituxan has generated strong growth in the NHL market since its launch, although Rituxan's market penetration Noun 1. market penetration - the extent to which a product is recognized and bought by customers in a particular market penetration - the act of entering into or through something; "the penetration of upper management by women" may have peaked. What factors will drive future growth in the NHL market? Where do opportunities lie in the treatment of NHL? How will emerging agents stack up against Rituxan? With the launch of new agents, cost will become a driving factor in NHL treatment. Which emerging therapies or drug classes will command the highest prices in the NHL market? How will third-party payers respond to the arrival of potent but potentially expensive NHL therapies? As many as 20 new therapies are in development for the treatment of NHL. Where will new therapies that arrive on the market fit alongside existing treatment regimens for NHL? What types of NHL will benefit most from new therapies? How will these agents be positioned in the market? What present agents, if any, will face competition? Scope Overview of non-Hodgkin's lymphoma: disease characteristics, risk factors, classification and staging, and diagnosis and prevalence. Lymphomas covered: follicular lymphoma follicular lymphoma n. See nodular lymphoma. follicular lymphoma Follicle center lymphoma A heterogeneous group of NHLs arising in follicular center cells, which comprises 50% of all NHLs in adults–US, , B-cell lymphomas, T-cell lymphomas, mantle cell lymphoma Mantle cell lymphoma (MCL) is one of the rarer of the non-Hodgkin's lymphomas, comprising about 6% of NHL cases.[1] There are only about 15,000 patients presently in the U.S. (The incidence seems to be somewhat higher in Europe. . Current therapies: overview of agents currently in use to treat NHL. Emerging therapies: a review of leading agents in development for NHL. Drug classes covered: novel chemotherapy agents, combination therapies, vaccines, monoclonal antibodies, radioimmunotherapies. Market outlook: our projections for how emerging agents could alter the NHL landscape. Content Outline: Executive Summary Strategic Considerations Stakeholder Implications Introduction Overview of Non-Hodgkin's Lymphoma Disease Characteristics and Risk Factors Disease Classification, Staging, and Grade Diagnosis and Prevalent and Incident Cases Current Therapies Emerging Therapies Novel Chemotherapy Agents Hana Bioscience's Marquibo Cephalon's Treanda Agents for Use in Combination with Rituxan Vaccines Genentech/Roche/Chugai's Avastin Immunomedics' Epratuzumab Biogen Idec's Galiximab Celgene's Revlimid Agents in Development for T-Cell Lymphomas Gloucester Pharmaceuticals' Romidepsin Seattle Genetics' SGN-30 Agents in Development for Mantle Cell Lymphoma Wyeth's Temsirolimus Genta's Genasense Millennium Pharmaceuticals' Velcade Agents in Development for Relapsed or Refractory NHL Genmab's HuMax-CD20 Eli Lilly's Enzastaurin Other Agents in Development Human Genome Sciences/GlaxoSmithKline's Mapatumumab Outlook for the NHL Market Tables: 1. Descriptions of Common Types of Non-Hodgkin's Lymphomas 2. The WHO Classification System for Non-Hodgkin's Lymphoma 3. Lymphoma Staging System Staging system A system based on how far the cancer has spread from its original site, developed to help the physician determine how best to treat the disease. Mentioned in: Neuroblastoma : Ann Arbor Classification Ann Arbor classification A system for staging Hodgkin's disease and guiding therapy; clinical data is added based on A–absence or B–presence of associated symptoms–eg, night sweats, fever or weight loss of > 10%; other Sx of Hodgkin's disease 4. Current Therapy Regimens for Non-Hodgkin's Lymphoma 5. Select Agents in Development for Non-Hodgkin's Lymphoma Figures: 1. Prevalent and Incident Cases of Non-Hodgkin's Lymphoma, 2005 2. Number of Agents in Development by Strategy Content Outline: Accentia Biopharmaceuticals Amgen Baxter Biogen Idec BioVest International Bristol-Myers Squibb Celgene Cephalon Ceph´a`lon n. 1. (Zool.) The head. Oncology Chugai EG Labo Eli Lilly Enzon Pharmaceuticals Favrille Fujisawa Deutschland Genentech Genitope Genmab GlaxoSmithKline Gloucester Pharmaceuticals Hana Bioscience Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. Immunomedics Inex Pharmaceuticals Kyowa Large Scale Biologics Merck Millennium Pharmaceuticals Pfizer Roche Seattle Genetics Wyeth For more information visit http://www.researchandmarkets.com/reports/c47405 Sources: Decision Resources |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion